AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20590481 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 17
Study 20590481 — intervention group
Group type: COMPARATOR
Intervention: Light touch
Number of subjects: 17
Study 20590481 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 17454518 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose = 4.3 mg/day, SD = 1.2)
Number of subjects: 22
Study 17454518 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (mean dose = 300 mg/day, SD = 66.7)
Number of subjects: 22
Study 15924813 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 545
Study 15924813 — intervention group
Group type: COMPARATOR
Intervention: Early conservative strategy
Number of subjects: 545
Study 12495317 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9697878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Cyclosporin A (CsA)
Number of subjects: 46
Study 9697878 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without Cyclosporin A (CsA)
Number of subjects: 46
Study 8570345 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Productive Syntax
Number of subjects: 29
Study 8570345 — intervention group
Group type: COMPARATOR
Intervention: Developmental Sentence Scoring
Number of subjects: 29
Study 2515160 — intervention group
Group type: EXPERIMENTAL
Intervention: New liquid formulation of Isocillin syrup
Number of subjects: 14
Study 2515160 — intervention group
Group type: EXPERIMENTAL
Intervention: New liquid formulation of Isocillin syrup plus ethanol
Number of subjects: 14
Study 2515160 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available penicillin V syrup containing ethanol as solubilizer
Number of subjects: 14
Study 2515160 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocillin film tablets
Number of subjects: 14
Study 365322 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 65
Study 365322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 31268872 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg/day)
Number of subjects: 72
Study 31268872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27899747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (n=1933)
Number of subjects: 3858
Study 27899747 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (n=1925)
Number of subjects: 3858
Study 27899747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3858
Study 27899747 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3858
Study 27899747 — intervention group
Group type: COMPARATOR
Intervention: Non-Asian group
Number of subjects: 3858
Study 26402868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) delivered in groups of 8 patients and 2 therapists or 4 patients and 1 therapist
Number of subjects: 204
Study 26402868 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 204
Study 26402868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 204
Study 22746285 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall psychopathy
Number of subjects: 483
Study 22746285 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive antisociality
Number of subjects: 483
Study 22746285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearless dominance
Number of subjects: 483
Study 22746285 — intervention group
Group type: EXPERIMENTAL
Intervention: Global psychopathy and impulsive antisociality
Number of subjects: 483
Study 21933039 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36
Study 21933039 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training
Number of subjects: 36
Study 21933039 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 19178132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily on days 1-3 and once daily on day 4
Number of subjects: 22
Study 19178132 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg once daily on days 1-4
Number of subjects: 22
Study 19178132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments together on days 1-4
Number of subjects: 22
Study 19178132 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran etexilate
Number of subjects: 22
Study 19178132 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 22
Study 19178132 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Dabigatran etexilate (combination treatment)
Number of subjects: 22
Study 17218919 — intervention group
Group type: EXPERIMENTAL
Intervention: Steamroller technique
Number of subjects: 40
Study 17218919 — intervention group
Group type: COMPARATOR
Intervention: Basic technique
Number of subjects: 40
Study 16032385 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased endothelin plasma levels during supine position and head-up tilt in subjects with vasovagal syncope
Number of subjects: 40
Study 16032385 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 40
Study 11926917 — intervention group
Group type: EXPERIMENTAL
Intervention: Retronasal olfactory function assessment
Number of subjects: 230
Study 11926917 — intervention group
Group type: EXPERIMENTAL
Intervention: Retronasal olfactory function in normosmic subjects
Number of subjects: 230
Study 11926917 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthonasal and retronasal identification of odors
Number of subjects: 230
Study 11926917 — intervention group
Group type: EXPERIMENTAL
Intervention: Retronasal testing
Number of subjects: 230
Study 11926917 — intervention group
Group type: EXPERIMENTAL
Intervention: Retronasal performance of anosmic patients
Number of subjects: 230
Study 11926917 — intervention group
Group type: COMPARATOR
Intervention: Comparison of anosmia of different origin
Number of subjects: 230
Study 9526179 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 198
Study 9526179 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 50-100 mg/day
Number of subjects: 198
Study 7786835 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitor
Number of subjects: 0
Study 7786835 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist (spironolactone)
Number of subjects: 0
Study 7786835 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACE inhibitor only)
Number of subjects: 0
Study 2710907 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (supervised, 3 times per week for 12 weeks)
Number of subjects: 27
Study 2710907 — intervention group
Group type: COMPARATOR
Intervention: Strength training (3 times per week for 12 weeks)
Number of subjects: 27
Study 2710907 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 27
Study 1203224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% benzalkonium chloride in rabbits
Number of subjects: 2
Study 1203224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% benzalkonium chloride in humans
Number of subjects: 2
Study 30906960 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with multiple sclerosis
Number of subjects: 46
Study 30906960 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46
Study 30906960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stability tasks
Number of subjects: 46
Study 30906960 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex walking scenario
Number of subjects: 46
Study 28636580 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotions
Number of subjects: 1346
Study 28636580 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1346
Study 25451868 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI above median
Number of subjects: 14806
Study 25451868 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT above median
Number of subjects: 14806
Study 25451868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cTnI and cTnT above median
Number of subjects: 14806
Study 25451868 — intervention group
Group type: EXPERIMENTAL
Intervention: One troponin above median
Number of subjects: 14806
Study 22960747 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% exercise at ambient temperatures of 20, 24, and 28 °C
Number of subjects: 7
Study 22960747 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% exercise at 28 °C
Number of subjects: 7
Study 21806314 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 6.25 mg once daily
Number of subjects: 480
Study 21806314 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg once daily
Number of subjects: 480
Study 21806314 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 480
Study 21806314 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 50 mg once daily
Number of subjects: 480
Study 21806314 — intervention group
Group type: COMPARATOR
Intervention: Voglibose 0.2 mg three times daily
Number of subjects: 480
Study 21806314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 21806314 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (all dosages)
Number of subjects: 480
Study 21806314 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 480
Study 19558008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg
Number of subjects: 75
Study 19558008 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine, 5 mg
Number of subjects: 75
Study 19558008 — intervention group
Group type: COMPARATOR
Intervention: Epinastine, 20 mg
Number of subjects: 75
Study 19558008 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine, 120 mg
Number of subjects: 75
Study 19558008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 15566589 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glucose levels
Number of subjects: 151
Study 15566589 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glucose concentration
Number of subjects: 151
Study 10511064 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 9
Study 10511064 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg R,R‐enantiomer
Number of subjects: 9
Study 10511064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7735495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pansalt (low-Na/high-K salt alternative)
Number of subjects: 40
Study 7735495 — intervention group
Group type: COMPARATOR
Intervention: Standard NaCl (control group)
Number of subjects: 40
Study 2285009 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/day)
Number of subjects: 10
Study 2285009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6165336 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for prophylaxis
Number of subjects: 100
Study 6165336 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics for prophylaxis
Number of subjects: 100
Study 6165336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Gram's stain procedure
Number of subjects: 100
Study 30615478 — intervention group
Group type: EXPERIMENTAL
Intervention: Generative retrieval (GR)
Number of subjects: 40
Study 30615478 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 40
Study 27904931 — intervention group
Group type: EXPERIMENTAL
Intervention: LHB tenodesis (LHB‐TD) in 49 patients
Number of subjects: 85
Study 27904931 — intervention group
Group type: COMPARATOR
Intervention: LHB tenotomy (LHB‐TT) in 36 patients
Number of subjects: 85
Study 25017013 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask treatment started after the completion of the Alt‐RAMEC procedure (Group I)
Number of subjects: 36
Study 25017013 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask treatment started simultaneously with the Alt‐RAMEC procedure (Group II)
Number of subjects: 36
Study 24952858 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA chelation + high-dose vitamins
Number of subjects: 1708
Study 24952858 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA chelation + placebo vitamins
Number of subjects: 1708
Study 24952858 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo infusion + active vitamins
Number of subjects: 1708
Study 24952858 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion + placebo vitamins
Number of subjects: 1708
Study 24952858 — intervention group
Group type: COMPARATOR
Intervention: Double active treatment (EDTA + high-dose vitamins) vs double placebo
Number of subjects: 1708
Study 24952858 — intervention group
Group type: COMPARATOR
Intervention: Double active treatment (EDTA + high-dose vitamins) vs double placebo in patients with diabetes
Number of subjects: 1708
Study 23072086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-hypothermia
Number of subjects: 90
Study 23072086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 23072086 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (mild-hypothermia + acupuncture)
Number of subjects: 90
Study 23072086 — intervention group
Group type: COMPARATOR
Intervention: Control (Acupuncture)
Number of subjects: 90
Study 19424699 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored protocols (Group 2)
Number of subjects: 120
Study 19424699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed injection parameters (Group 1)
Number of subjects: 120
Study 19424699 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocols (Group 3)
Number of subjects: 120
Study 17329192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (1200/30 mg/m2, days 1 and 8)
Number of subjects: 252
Study 17329192 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2, days 1 and 8)
Number of subjects: 252
Study 17329192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine
Number of subjects: 252
Study 17329192 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 252
Study 16113429 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 16113429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 0
Study 11260417 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/Lactate (B/L) solution
Number of subjects: 106
Study 11260417 — intervention group
Group type: COMPARATOR
Intervention: Control (C) solution
Number of subjects: 106
Study 9482763 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg of zinc as zinc sulfate, 4 mL beverage daily for an average of 6.9 months)
Number of subjects: 89
Study 9482763 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 89
Study 9482763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 8015632 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation (ASTA H995) 125 mg
Number of subjects: 12
Study 8015632 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation (ASTA H995) 250 mg
Number of subjects: 12
Study 8015632 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation (ASTA H995) 275 mg
Number of subjects: 12
Study 8015632 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation
Number of subjects: 12
Study 8015632 — intervention group
Group type: COMPARATOR
Intervention: L-dopa standard preparation
Number of subjects: 12
Study 30047132 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralaminar approach (group PL)
Number of subjects: 42
Study 30047132 — intervention group
Group type: COMPARATOR
Intervention: Intercostal approach (group IC)
Number of subjects: 42
Study 27698557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi qigong (TCQ) training, 2 sessions of 60 minutes each week for 2 months
Number of subjects: 52
Study 27698557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi qigong (TCQ) training
Number of subjects: 52
Study 27698557 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 52
Study 25504466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (RTP) + Cognitive Stimulation (CS)
Number of subjects: 90
Study 25504466 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch (RTP)
Number of subjects: 90
Study 23630366 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 54
Study 23630366 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 54
Study 20627703 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT pain sensitivity haplotype (SNPs rs6269, rs4633, rs4818, rs4680)
Number of subjects: 159
Study 20627703 — intervention group
Group type: EXPERIMENTAL
Intervention: rs165599 SNP
Number of subjects: 159
Study 20627703 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 159
Study 20002476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (force titrated to 45 mg/day)
Number of subjects: 1515
Study 20002476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1515
Study 17218108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1 million IU)
Number of subjects: 300
Study 17218108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2.5g)
Number of subjects: 300
Study 17218108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 15051755 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy (60 Gy in 30 fractions over 6 weeks)
Number of subjects: 100
Study 15051755 — intervention group
Group type: COMPARATOR
Intervention: Shorter course of radiation therapy (40 Gy in 15 fractions over 3 weeks)
Number of subjects: 100
Study 11280620 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspect A‐1000 measuring BIS
Number of subjects: 28
Study 11280620 — intervention group
Group type: EXPERIMENTAL
Intervention: Drager pEEG measuring SEF90%
Number of subjects: 28
Study 9476566 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0
Study 9476566 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0
Study 7614865 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan of the hip
Number of subjects: 30
Study 7614865 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiographic assessment
Number of subjects: 30
Study 3360951 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary short-term abstinence from alcohol for 3 weeks
Number of subjects: 36
Study 3360951 — intervention group
Group type: COMPARATOR
Intervention: Control group (drank as usual)
Number of subjects: 36
Study 28980055 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (Group D)
Number of subjects: 60
Study 28980055 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg tranexamic acid (Group T)
Number of subjects: 60
Study 28980055 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone and 10 mg/kg tranexamic acid (Group DT)
Number of subjects: 60
Study 28980055 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 60
Study 27080916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 21 days after SWL
Number of subjects: 60
Study 27080916 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg daily for 21 days after SWL
Number of subjects: 60
Study 27080916 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 21 days after SWL
Number of subjects: 60
Study 25914193 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day)
Number of subjects: 53
Study 25914193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 24137674 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 22
Study 24137674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 22
Study 24137674 — intervention group
Group type: COMPARATOR
Intervention: BIS85
Number of subjects: 22
Study 20934876 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous target cues
Number of subjects: 40
Study 20934876 — intervention group
Group type: EXPERIMENTAL
Intervention: End-point cues
Number of subjects: 40
Study 20934876 — intervention group
Group type: EXPERIMENTAL
Intervention: End target cues
Number of subjects: 40
Study 20934876 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous targets
Number of subjects: 40
Study 19049552 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based patient decision aid (DA)
Number of subjects: 297
Study 19049552 — intervention group
Group type: COMPARATOR
Intervention: Standard information (Control Group)
Number of subjects: 297
Study 16175942 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 20
Study 16175942 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/day
Number of subjects: 20
Study 16175942 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day + Irbesartan 300 mg/day
Number of subjects: 20
Study 16175942 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 12925633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated external fixation pins
Number of subjects: 17
Study 12925633 — intervention group
Group type: COMPARATOR
Intervention: Uncoated external fixation pins
Number of subjects: 17
Study 10745299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 77
Study 10745299 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study 8634617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led programme using a family centered approach, with follow up according to degree of risk
Number of subjects: 7008